Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.
Melanoma, Cancer Immunotherapy, and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy,1.
Paolo Antonio
PA
Ascierto
Ester
E
Simeone
Vanna Chiarion
VC
Sileni
Michele
M
Del Vecchio
Paolo
P
Marchetti
Gian Carlo Antonini
GC
Cappellini
Ruggero
R
Ridolfi
Francesco
F
de Rosa
Francesco
F
Cognetti
Virginia
V
Ferraresi
Alessandro
A
Testori
Paola
P
Queirolo
Maria Grazia
MG
Bernengo
Michele
M
Guida
Luca
L
Galli
Mario
M
Mandalà
Carolina
C
Cimminiello
Gaetana
G
Rinaldi
Fabrizio
F
Carnevale-Schianca
Michele
M
Maio
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D000074324:Ipilimumab; D007558:Italy; D053208:Kaplan-Meier Estimate; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009154:Mutation; D010091:Oximes / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D013449:Sulfonamides / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D000077484:Vemurafenib; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007093:Imidazoles; D007211:Indoles; D000074324:Ipilimumab; D010091:Oximes; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib